liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Theorin, Niklas
Publications (4 of 4) Show all publications
Mohty, M., Labopin, M., Milpied, N.-J., Blaise, D., Petersen, E., Theorin, N., . . . Socie, G. (2008). Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). In: American Society of Hematology Meeting: in: Blood Volume 112, Issue 11 (pp. 134-135). , 112(11)
Open this publication in new window or tab >>Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)
Show others...
2008 (English)In: American Society of Hematology Meeting: in: Blood Volume 112, Issue 11, 2008, Vol. 112, no 11, p. 134-135Conference paper, Published paper (Refereed)
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-17162 (URN)
Available from: 2009-03-07 Created: 2009-03-07 Last updated: 2009-08-19
Mohty, M., Labopin, M., Tabrizzi, R., Theorin, N., Fauser, A., Rambaldi, A., . . . Rocha, V. (2008). Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica, 93(2), 303-306
Open this publication in new window or tab >>Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation
Show others...
2008 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 93, no 2, p. 303-306Article in journal (Refereed) Published
Abstract [en]

This retrospective study reported the outcome of 97 adult acute lymphoblastic leukemia patients who received a reduced-intensity conditioning allogeneic stem cell transplantation. With a median follow-up of 2.8 years, two year overall-survival, leukemia-free survival and non-relapse mortality were significantly better in patients transplanted in first complete remission (CR1, 52±9%, 42±10%, and 18±7% respectively) compared with those transplanted in more advanced phase (p=0.003, p=0.002 and p=0.01 respectively). In multivariate analysis, disease status (CR1 vs. advanced, p=0.001) and chronic graft-vs-host disease (p=0.01) were associated with an improved overall-survival, suggesting that reduced-intensity conditioning allogeneic stem cell transplantation is feasible in patients with high risk lymphoblastic leukemia in remission at transplantation. ©2008 Ferrata Storti Foundation.

Keywords
Acute lymphoblastic leukemia, Allogeneic SCT
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-46989 (URN)10.3324/haematol.11960 (DOI)
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2017-12-13
Gorin, N.-C., Labopin, M., Boiron, J.-M., Theorin, N., Littlewood, T., Slavin, S., . . . Rocha, V. (2006). Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: Higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond - The acute leukemia . Journal of Clinical Oncology, 24(24), 3959-3966
Open this publication in new window or tab >>Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: Higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond - The acute leukemia
Show others...
2006 (English)In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 24, no 24, p. 3959-3966Article in journal (Refereed) Published
Abstract [en]

Purpose Nucleated cell dose is an important and modifiable factor in hematopoietic stem cell transplantation (HSCT), however its association with outcomes in the context of reduced intensity conditioning regimen (RIC) HSCT for adults with acute myelocytic leukemia (AML) is not known. Patients and Methods From 1998 to 2003, 253 patients with de novo AML, received transplants with RIC and peripheral blood from a genoidentical donor. Median age was 55 years (range, 18 to 72) and the median follow-up was 17 months (range, 2 to 67). One hundred forty one patients received transplants in first remission (CRI), 47 received transplants in second remission (CR2), and 65 patients received transplants in a more advanced phase. Fludarabin-based RIC was used in, 91%, of patients and low-dose (<4 Gy) total-body radiation in 23% of patients. The median nucleated and CD34 cell dose infused were 9.1 x 10(8)/kg and 5.8 x 10(6)/kg, respectively. Results,. Overall, 2-year leukemia-free survival (LFS) was 41% +/- 4% and it was 46% +/- 5% for patients receiving a higher cell dose (>9.1 x 10(8)/kg) and 37% +/- 5% for the remainders (P = .03). Higher cell doses exclusively benefited patients who received transplantations in CR2 or beyond, with LFS of 47 +/- 8 versus 20 +/- 8, with no detectable effect for patients who received transplants in CR1. In a multivariate analysis of the overall patient population, higher nucleated cell dose cells were associated with higher LFS (P = .04), higher incidence of chronic graft-versus-host disease (P = .01), and there was a trend towards a lower relapse incidence (P = .06). Interestingly, CD34+ cell dose was not associated with any outcomes. Conclusion Nucleated cell dose is an important factor that can be modified to improve results of RIC for patients with AML transplanted later than om CR1.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-45997 (URN)10.1200/JCO.2006.05.5855 (DOI)
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2017-12-13
Juliusson, G., Theorin, N., Karlsson, K., Frödin, U. & Malm, C. (2006). Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: Influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplantation, 37(5), 503-510
Open this publication in new window or tab >>Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: Influence of Campath dose on lymphoid recovery, mixed chimerism and survival
Show others...
2006 (English)In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 37, no 5, p. 503-510Article in journal (Refereed) Published
Abstract [en]

Sixty-nine consecutive patients (median age 54 years) were prospectively enrolled in a single-institution protocol for allogeneic transplantation with adjusted non-myeloablative fludarabine-melfalan-based conditioning including cyclosporin A and MMF, and one of three modes of serotherapy. Thirty-one donors (45%) were unrelated. The first cohort of 29 had ATG (Thymoglobulin 2 mg/kg × 3 days), the subsequent 26 had Campath 30 mg × 3 days subcutaneously, and the final cohort of 14 had 30 mg Campath once. The groups were similar as regards age, diagnosis and risk factors. Campath-patients had no acute toxicity, fewer days with fever and antibiotics, and required fewer transfusions than ATG-treated patients. 3-d-Campath patients showed lower lymphocyte counts from day + 4, and CD4 +, CD8 +, CD19 + and NK cells recovered slower than in ATG-treated patients. More Campath patients developed mixed chimerism that required DLI. 3-d-Campath induced more serious and opportunistic infections than ATG, which resulted in a greater non-relapse mortality and an impaired overall survival despite a low tumor-related mortality. The change of the Campath dosing schedule to one dose abrogated the deleterious effect of 3-d-Campath on immune recovery, severe infections and survival. Subcutaneous Campath is simple and provides strong immune suppression with no early toxicity, but dose limitation to 30 mg once is recommended. © 2006 Nature Publishing Group. All rights reserved.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-37781 (URN)10.1038/sj.bmt.1705263 (DOI)38533 (Local ID)38533 (Archive number)38533 (OAI)
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2017-12-13
Organisations

Search in DiVA

Show all publications